Last $22.92 USD
Change Today +0.64 / 2.87%
Volume 85.2K
SRDX On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

surmodics inc (SRDX) Snapshot

Open
$22.19
Previous Close
$22.28
Day High
$23.10
Day Low
$22.19
52 Week High
03/7/14 - $25.99
52 Week Low
10/1/14 - $18.00
Market Cap
296.2M
Average Volume 10 Days
56.1K
EPS TTM
$0.93
Shares Outstanding
12.9M
EX-Date
--
P/E TM
24.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for SURMODICS INC (SRDX)

surmodics inc (SRDX) Related Bloomberg News

View More Bloomberg News

surmodics inc (SRDX) Related Businessweek News

No Related Businessweek News Found

surmodics inc (SRDX) Details

SurModics, Inc. provides surface modification and in vitro diagnostic technologies to the healthcare industry. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neurovascular, urology, and other markets. The In Vitro Diagnostics segment provides component products and technologies that include protein stabilization reagents, substrates, antigens, and surface coatings for diagnostic immunoassay and molecular tests, and biomedical research applications. SurModics, Inc. markets its technologies and products worldwide through direct sales force consisting of sales professionals. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

120 Employees
Last Reported Date: 12/5/14
Founded in 1979

surmodics inc (SRDX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $443.7K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $252.2K
Senior Vice President and General Manager of ...
Total Annual Compensation: $285.6K
Senior Vice President of Legal & Human Resour...
Total Annual Compensation: $285.6K
Vice President of Corporate Development & Str...
Total Annual Compensation: $266.5K
Compensation as of Fiscal Year 2014.

surmodics inc (SRDX) Key Developments

SurModics, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2014; Reaffirms Earnings Guidance for Fiscal 2015

SurModics, Inc. announced unaudited consolidated earnings results for the first quarter ended September 30, 2014. For the quarter, the company reported total revenue was $14,205,000 compared to $13,883,000 for the same period a year ago. Income from operations was $5,034,000 compared to $4,329,000 for the same period a year ago. Income before income taxes was $5,084,000 compared to $5,096,000 for the same period a year ago. Net income was $3,614,000 compared to $3,630,000 for the same period a year ago. Basic and diluted net income per share was $0.27 compared to $0.26 for the same period a year ago. Net cash provided by operating activities from continuing operations was $5,530,000 compared to $4,250,000 for the same period a year ago. Purchases of property and equipment were $41,000 compared to $56,000 for the same period a year ago. Adjusted net income was $3,413,000 or $0.25 per diluted share compared to $2,949,000 or $0.21 per diluted share for the same period a year ago. The company reaffirmed its previously stated guidance for fiscal 2015. The company expected full-year revenue to be in the range of $57.0 to $60.0 million, and diluted GAAP earnings to be in the range of $0.85 per share to $0.95 per share. The fiscal 2015 earnings per share guidance includes an increase of approximately 5% to 7% in research and development investment over fiscal 2014 levels, primarily related to the drug coated balloon program; an assumed 13.2 million diluted shares outstanding; and a 33.0% to 35.0% income tax rate. The company’s earnings per share and income tax rate guidance exclude the impact of any strategic investment gains and losses. GAAP cash flow from operating activities is expected to range between $16.5 million and $18.0 million for fiscal 2015, unchanged from prior guidance. Capital expenditures for fiscal 2015 are projected to range between $2.2 million and $2.5 million, which is also unchanged.

SurModics, Inc. to Report Q1, 2015 Results on Jan 29, 2015

SurModics, Inc. announced that they will report Q1, 2015 results at 5:00 PM, US Eastern Standard Time on Jan 29, 2015

SurModics, Inc., Q1 2015 Earnings Call, Jan 29, 2015

SurModics, Inc., Q1 2015 Earnings Call, Jan 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRDX:US $22.92 USD +0.64

SRDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.34 USD -0.04
Biolase Inc $2.56 USD -0.0001
Cerus Corp $5.34 USD -0.12
Cutera Inc $13.30 USD -0.31
STAAR Surgical Co $6.00 USD +0.14
View Industry Companies
 

Industry Analysis

SRDX

Industry Average

Valuation SRDX Industry Range
Price/Earnings 25.8x
Price/Sales 5.2x
Price/Book 3.7x
Price/Cash Flow 24.7x
TEV/Sales 4.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SURMODICS INC, please visit www.surmodics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.